Real-world efficacy and safety of PD-1 inhibitors in patients living with HIV and cancer: a retrospective cohort study - Takeaways - MDSpire

Real-world efficacy and safety of PD-1 inhibitors in patients living with HIV and cancer: a retrospective cohort study

  • By

  • Xiaola Xue

  • Juyi Wu

  • Zhenpeng Tan

  • Chunyu Tian

  • Qiong Li

  • Shujuan Zhou

  • Yuchao Xia

  • Shaojie Yang

  • Xuan Yang

  • June 24, 2026

  • 0 min

Share

  • 1

    PD-1 inhibitors were assessed for efficacy and safety in HIV-positive cancer patients with advanced immunosuppression.

  • 2

    The study included 90 patients, with 70 HIV-positive and 20 HIV-negative, and used propensity score matching for analysis.

  • 3

    Objective response rates and disease control rates were comparable between HIV-positive and HIV-negative groups.

  • 4

    Severe treatment-related adverse events occurred exclusively in the HIV-positive cohort, but overall toxicity rates remained low.

  • 5

    HIV status was not an independent prognostic factor for treatment outcomes, and immune restoration was observed in patients with low CD4+ counts.

Original Source(s)

Real-world efficacy and safety of PD-1 inhibitors in patients living with HIV and cancer: a retrospective cohort study

  • by Xiaola Xue, Juyi Wu, Zhenpeng Tan, Chunyu Tian, Qiong Li, Shujuan Zhou, Yuchao Xia, Shaojie Yang, Xuan Yang

  • June 24, 2026

Related Content

Metabolic regulation and immunosuppressive functions of lipid-associated macrophages in pancreatic ductal adenocarcinoma

Case report and literature review: key clinical management points and prognostic analysis of paraganglioma of the urinary bladder

The Long-Term Sequelae and Clinical Workload Resulting from Toxicities of Immune Checkpoint Inhibitor (ICI) Therapy in Patients with Cancer